Compare IOSP & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOSP | STOK |
|---|---|---|
| Founded | 1938 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1998 | 2019 |
| Metric | IOSP | STOK |
|---|---|---|
| Price | $82.45 | $32.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $93.00 | $39.20 |
| AVG Volume (30 Days) | 189.5K | ★ 955.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ 228.87 | 92.73 |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,778,000,000.00 | $184,420,000.00 |
| Revenue This Year | $5.96 | N/A |
| Revenue Next Year | $6.10 | $77.49 |
| P/E Ratio | $68.11 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $65.51 | $11.43 |
| 52 Week High | $92.14 | $40.22 |
| Indicator | IOSP | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 55.06 | 61.30 |
| Support Level | $78.95 | $30.34 |
| Resistance Level | $87.82 | $35.11 |
| Average True Range (ATR) | 2.11 | 1.47 |
| MACD | -0.32 | 0.40 |
| Stochastic Oscillator | 37.73 | 82.42 |
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Performance Chemicals segment that derives maximum revenue, provides technology-based solutions for its customers' processes or products in personal care, home care, agrochemical, construction, mining and other industrial markets. The Fuel Specialties segment develops, manufactures, blends, markets and supplies a range of specialty chemical products used as additives in diesel, jet, marine, fuel oil and other fuels. The Oilfield Services segment develops and markets chemical solutions for drilling, completion, production, DRA and oil and gas applications.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.